Biotechnology company Anixa Biosciences has partnered with Cytovance Biologics to support the Phase II clinical trial of a breast cancer vaccine. The vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a lactation-associated protein that is typically expressed only in breast tissue during lactation but which re-emerges in many forms of breast cancer. By generating an immune response against α-lactalbumin-expressing cells, the vaccine […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!